At Xintela, we continue to work intensively to achieve milestones. We
now have full focus on the preparation of the GMP (Good Manufacturing Practice)
production of our stem cells and preparing for clinical trials in both horses
and humans. At the end of May, we announced the signing of a Memorandum of
Understanding agreement with the leading European cell therapy company, CO.DON,
after successful validation of our quality assurance assay, XACT™. This shows
that our technology platform is internationally competitive and that
possibilities to secure new collaborative agreements on Xintela’s quality
assurance biomarkers for cell therapy are very good. At the same time, we
continue the work to identify partners for the glioblastoma project and our
Antibody Drug Conjugate (ADC) therapy.
Recently, we were very pleased that Xintela, together with other players from
Academia, healthcare and industry, received a large government investment to
stimulate the development of cell and gene therapy in Sweden. We will explain
more about this multimillion SEK investment later in this newsletter.
You can also read an interview with Xintela’s new Board Member, Keld
Søndergaard, who brings with him valuable experience in finance and corporate
development. Moreover, Thomas Areschoug tells us about the partnership
conferences that we have participated in this summer, one in London in May and
the large BIO Conference in the USA in June.
I would also like to take the opportunity to wish you all a lovely summer.
Evy Lundgren-Åkerlund
CEO, Xintela AB
